United Therapeutics Corporation Payments to Acquire Long-term Investments
United Therapeutics Corporation (UTHR) reported Payments to Acquire Long-term Investments of $1.50 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireLongtermInvestments · last filed 2022-11-02
- United Therapeutics Corporation payments to acquire long-term investments for the quarter ending 2021-12-31 was $0.00.
- United Therapeutics Corporation payments to acquire long-term investments for the quarter ending 2020-12-31 was $0.00.
- United Therapeutics Corporation payments to acquire long-term investments for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation payments to acquire long-term investments for the quarter ending 2019-12-31 was $0.00.
- United Therapeutics Corporation payments to acquire long-term investments for fiscal 2021 was $0.00.
- United Therapeutics Corporation payments to acquire long-term investments for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- United Therapeutics Corporation payments to acquire long-term investments for fiscal 2019 was $8.00M, a 60.00% increase from fiscal 2018.
- United Therapeutics Corporation payments to acquire long-term investments for fiscal 2018 was $5.00M, a 91.72% decline from fiscal 2017.
| Period end | Payments to Acquire Long-term Investments 3 month | Payments to Acquire Long-term Investments 6 month | Payments to Acquire Long-term Investments 9 month | Payments to Acquire Long-term Investments 12 month |
|---|---|---|---|---|
| 2022-09-30 | $1.50M 10-Q · filed 2022-11-02 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-07-29 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.00M derived: sum of 2 quarters · filed 2022-02-24 | $1.00M derived: sum of 3 quarters · filed 2022-02-24 | $8.00M 10-K · filed 2022-02-24 |
| 2019-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $1.00M derived: sum of 2 quarters · filed 2020-10-28 | $8.00M 10-Q · filed 2020-10-28 | $8.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $7.00M 10-Q · filed 2020-07-29 | $7.00M derived: sum of 3 quarters · filed 2021-02-24 | $7.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $7.00M 10-Q · filed 2020-04-29 | $7.00M derived: sum of 2 quarters · filed 2021-02-24 | $7.00M derived: sum of 3 quarters · filed 2021-02-24 | $7.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $0.00 derived: sum of 3 quarters · filed 2021-02-24 | $5.00M 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | $5.00M 10-Q · filed 2019-10-30 | $10.10M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $5.00M 10-Q · filed 2019-07-31 | $10.10M derived: sum of 3 quarters · filed 2020-02-26 | $40.30M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $5.00M 10-Q · filed 2019-05-01 | $10.10M derived: sum of 2 quarters · filed 2020-02-26 | $40.30M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $35.30M derived: sum of 2 quarters · filed 2020-02-26 | $60.40M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $30.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $55.30M 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | $25.10M 10-Q · filed 2018-08-01 | |||
| 2016-12-31 | $28.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $28.40M derived: sum of 2 quarters · filed 2019-02-27 | $36.00M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $7.60M 10-Q · filed 2017-10-25 | ||
| 2016-06-30 | $7.60M 10-Q · filed 2017-07-27 | |||
| 2015-12-31 | $54.20M 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |